QNCX
Quince Therapeutics, Inc.
$18.58
-0.71 (-3.68%)
At close · Jul 15
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources as of the issuance of these unaudited condensed consolidated financial statements, management concluded that substantial doubt exists with respect to the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$296.35M
Shares
16,300,740
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-12-18 | $75,000,000 | $53,100,000 | 2026-03-31 | — | 10-Q , filed 2026-05-11 |